Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213156 | 0.80 | ALDH1A1 (0.44) | HCRTR2TSHRALDH1A1HPGD | |
| SCHEMBL17865363 | 0.80 | HCRTR2 (0.38) | HCRTR2TSHRALDH1A1HPGD | |
| SCHEMBL24630407 | 0.79 | COPS5 (0.43) | TSHRALDH1A1HPGDGFERMAPK1 | |
| SCHEMBL17076691 | 0.79 | HCRTR2 (0.37) | HCRTR2TSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL12659982 | 0.76 | PTGS1 (0.32) | TSHRHPGDMAPK1 | |
| SCHEMBL13379444 | 0.72 | L3MBTL1 (0.33) | TSHRALDH1A1HPGDGFER | |
| SCHEMBL12869023 | 0.66 | ALDH1A1 (0.30) | TSHRALDH1A1HPGD | |
| SCHEMBL12391743 | 0.61 | FBP1 (0.33) | — | |
| SCHEMBL9860567 | 0.60 | ALDH1A1 (0.36) | TSHRALDH1A1HPGD | |
| SCHEMBL26564430 | 0.59 | CYP1A2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828368-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828368-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160176858-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176858-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885TSHR 284/4885ALDH1A1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.